RxDoctor Payments Data

Jesse Naghi, MD

Interventional Cardiology · El Cajon, CANPI 1386896736

Payments from drug & device makers

$23,687in general payments, 2019–2025

Across 919 payments — averaging $25.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$5K
  • Medtronic$2K
  • Abbott$2K
  • Boston Scientific$2K
  • Novartis$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • plus $10K from 54 others

What the payments were for

  • Consulting fees$2001%
  • Travel & lodging$1,2475%
  • Food & beverage$22,07893%
  • Education$1621%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Edwards Lifesciences63$5,192
Medtronic(3 entities)82$2,271
Abbott60$1,736
Boston Scientific85$1,669
Novartis100$1,416
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)57$1,095
Abiomed33$1,042
Amgen48$869
AstraZeneca35$759
Cvrx, Inc.32$694
Biotronik Inc.18$562
Boehringer Ingelheim19$445
Actelion Pharmaceuticals US, Inc.59$445
Johnson & Johnson31$442
Pfizer22$395
Merck15$317
Philips North America LLC15$306
Shockwave Medical, Inc3$285
Esperion Therapeutics, Inc.17$247
Penumbra, Inc.5$222
Cardiovascular Systems Inc.4$203
Heartflow, Inc.4$200
Merit Medical Systems Inc1$200
W. L. Gore & Associates, Inc.2$174
Impulse Dynamics (USA) Inc.6$166
Chiesi USA, Inc.9$151
Scpharmaceuticals Inc.6$147
Cardiva Medical, Inc.6$136
Bardy Diagnostics, Inc.8$127
E.r. Squibb & Sons, L.L.C.7$120
Braemar Manufacturing, LLC1$114
Acera Surgical, Inc.1$107
ZOLL Circulation Inc1$98
Kiniksa Pharmaceuticals, Ltd.5$96
Bard Peripheral Vascular, Inc.4$93
Novo Nordisk4$87
Endologix LLC1$83
Cardinal Health 200 LLC5$82
Kiniksa Pharmaceuticals International, PLC4$75
Cathworks, Inc.1$73
Regeneron Healthcare Solutions, Inc.4$71
Acutus Medical, Inc.2$57
Lexicon Pharmaceuticals, Inc.3$55
Kestra Medical Technology Services, Inc.2$54
Daiichi Sankyo Inc.3$54
Inari Medical, Inc.2$51
Irhythm Technologies, Inc.3$51
Amarin Pharma, Inc.2$40
Angiodynamics, Inc.2$38
Alnylam Pharmaceuticals Inc.2$31
Sanofi-aventis U.S. LLC2$30
Getinge USA Sales, LLC1$27
Acell, Inc.1$24
Stryker1$22
Tactile Systems Technology Inc1$20
Atricure, Inc.1$19
Saranas, Inc.1$18
Vivaquant Inc, Dba Rhythm Express1$15
Amryt Pharma Holdings Ltd1$15
BD1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,687 in reported general payments places this provider in the 65th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$636,247
Medicare patients
943
Services billed
4,424

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan159$172,984
EliquisApixaban127$130,020
XareltoRivaroxaban106$116,886
BrilintaTicagrelor113$63,219
JardianceEmpagliflozin30$37,714
FarxigaDapagliflozin Propanediol15$21,295
Repatha SureclickEvolocumab21$17,872
NexlizetBempedoic Acid/Ezetimibe21$16,711
Atorvastatin Calcium315$3,157
Varenicline Tartrate14$3,111
Bumetanide34$2,070
Metoprolol Succinate137$1,826
Nebivolol Hcl18$1,590
Losartan Potassium211$1,537
Verapamil ErVerapamil Hcl47$1,042

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$1,416$172,984159 claims
PfizerEliquis$395$130,020127 claims
Johnson & JohnsonXarelto$442$116,886106 claims
AstraZenecaBrilinta, Farxiga$759$84,514128 claims
Boehringer IngelheimJardiance$445$37,71430 claims
Esperion Therapeutics, Inc.Nexlizet$247$16,71121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in El Cajon

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →